196 related articles for article (PubMed ID: 36230734)
1. TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB.
Xing J; Chen W; Chen K; Zhu S; Lin F; Qi Y; Zhang Y; Han S; Rao T; Ruan Y; Zhao S; Yu W; Cheng F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230734
[TBL] [Abstract][Full Text] [Related]
2. Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.
Hu CY; Su BH; Lee YC; Wang CT; Yang ML; Shen WT; Fu JT; Chen SY; Huang WY; Ou CH; Tsai YS; Kuo FC; Shiau AL; Shieh GS; Wu CL
J Biomed Sci; 2022 Dec; 29(1):104. PubMed ID: 36471329
[TBL] [Abstract][Full Text] [Related]
3. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
4. NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Int J Oncol; 2016 Jan; 48(1):225-34. PubMed ID: 26647959
[TBL] [Abstract][Full Text] [Related]
5. Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway.
Li C; Su H; Ruan C; Li X
Folia Histochem Cytobiol; 2021; 59(1):40-48. PubMed ID: 33577073
[TBL] [Abstract][Full Text] [Related]
6. BRD4 promotes the migration and invasion of bladder cancer cells through the Sonic hedgehog signaling pathway and enhances cisplatin resistance.
Liu T; Zhang Z; Wang C; Huang H; Li Y
Biochem Cell Biol; 2022 Apr; 100(2):179-187. PubMed ID: 35167374
[TBL] [Abstract][Full Text] [Related]
7. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
[TBL] [Abstract][Full Text] [Related]
8. ROC1 promotes the malignant progression of bladder cancer by regulating p-IκBα/NF-κB signaling.
Wu Q; Zhou X; Li P; Ding M; You S; Xu Z; Ye J; Chen X; Tan M; Wang J; Wang W; Qiu J
J Exp Clin Cancer Res; 2021 May; 40(1):158. PubMed ID: 33962660
[TBL] [Abstract][Full Text] [Related]
9. High Expression of Nuclear Transcription Factor-κB is Associated with Cisplatin Resistance and Prognosis for Ovarian Cancer.
Kan Y; Liu J; Li F
Cancer Manag Res; 2020; 12():8241-8252. PubMed ID: 32982420
[TBL] [Abstract][Full Text] [Related]
10. Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation.
Guan Z; Sun Y; Mu L; Jiang Y; Fan J
BMC Cancer; 2022 Mar; 22(1):240. PubMed ID: 35246056
[TBL] [Abstract][Full Text] [Related]
11. TRIM29 Overexpression Promotes Proliferation and Survival of Bladder Cancer Cells through NF-κB Signaling.
Tan ST; Liu SY; Wu B
Cancer Res Treat; 2016 Oct; 48(4):1302-1312. PubMed ID: 26987391
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer.
Sun Y; Guan Z; Liang L; Cheng Y; Zhou J; Li J; Xu Y
Oncol Rep; 2016 Mar; 35(3):1549-56. PubMed ID: 26717965
[TBL] [Abstract][Full Text] [Related]
13. Induction of Apoptosis and Inhibition of EGFR/NF-κB Signaling Are Associated With Regorafenib-sensitized Non-small Cell Lung Cancer to Cisplatin.
Wu JY; Weng YS; Chiou YC; Hsu FT; Chiang IT
In Vivo; 2021; 35(5):2569-2576. PubMed ID: 34410944
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.
Chen Y; Huang M; Lu J; Zhang Q; Wu J; Peng S; Chen S; Zhang Y; Cheng L; Lin T; Chen X; Huang J
Environ Toxicol; 2024 Feb; 39(2):509-528. PubMed ID: 37310098
[TBL] [Abstract][Full Text] [Related]
15. TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway.
Wang X; Sun D; Tai J; Chen S; Yu M; Ren D; Wang L
J Exp Clin Cancer Res; 2018 Feb; 37(1):27. PubMed ID: 29439714
[TBL] [Abstract][Full Text] [Related]
16. Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner.
Sun Y; Guan Z; Zhao W; Jiang Y; Li Q; Cheng Y; Xu Y
Int J Oncol; 2017 Oct; 51(4):1219-1226. PubMed ID: 28791405
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
18. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
[TBL] [Abstract][Full Text] [Related]
19. Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor-κB-dependent manner.
Shen M; Duan X; Zhou P; Zhou W; Wu X; Xu S; Chen Y; Tao Z
Mol Med Rep; 2015 Feb; 11(2):783-90. PubMed ID: 25369740
[TBL] [Abstract][Full Text] [Related]
20. URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.
Wu M; Chen J; Wang Y; Hu J; Liu C; Feng C; Zeng X
Oncotarget; 2015 Oct; 6(31):30887-901. PubMed ID: 26429874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
